NCT05931445Active, not recruiting
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
Multicenter, Open-label, Randomized, Controlled Study to Test the Utility of Electronic Patient-reported Outcome (ePRO) Monitoring in Patients With Unresectable Advanced Cancers or Metastatic/Recurrent Solid Tumors
Source: ClinicalTrials.gov · Last updated 23 Apr 2024
Brief summary (registry, in English)
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic drug therapy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 5 Jun 2023
- Start date
- 26 Jan 2021
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Comprehensive Support Project for Oncology Research
- Diseases
- Head and neck cancer, Endometrial cancer, Lung cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer, Ovarian cancer
- NCT number
- NCT05931445
What you commit to
- Study type: Interventional
- Planned participants: 500
- From 26 Jan 2021 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The following are exclusion criteria for individual types of cancer 1) Breast cancer
- Scheduled to receive or currently receiving endocrine therapy (including endocrine therapy in combination with other agents) for hormone receptor-positive breast cancer
- Scheduled to receive or currently receiving first regimen of anti-HER2 therapy for HER2-positive disease 2) Liver cancer
- Hepatic function of Child-Pugh B/C
- Undergoing or scheduled to undergo radiation therapy for curative purposes
Other illness
- Deemed otherwise unsuitable for the study by the investigator or sub-investigator
- Notes:
- If the disease has relapsed during perioperative adjuvant chemotherapy or within 24 weeks after adjuvant chemotherapy, the adjuvant chemotherapy will be considered as the first regimen of adjuvant chemotherapy.
- Does not include endocrine therapy for breast cancer.
Other
- Has undergone four or more regimens of pharmacotherapy for advanced, metastasized, or relapsed solid tumors\*Notes 1, 2
- Currently participating in a study where PRO is tracked and the results are passed on to a physician
Who the study is looking for
- Unresectable, advanced, metastasized, or relapsed solid tumors (Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Stomach Cancer, Endometrial Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck)
- Expected to be able to undergo treatment or observation for at least 6 months at the study site
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2
- Receiving systemic anticancer mono- or combination pharmacotherapy (e.g., cytotoxic anticancer agents, molecularly targeted drugs, and immune checkpoint inhibitors) at enrollment or scheduled to begin such therapy within 1 month from the date of enrollment (In principle, patients should be receiving pharmacotherapy on an out-patient basis.)
- Capable of using electronic device (includes cases needing some assistance)
- Aged 18 years or older at informed consent
- Written consent for the study personally obtained from the subject
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kobe University Graduate School Coordinator of this site? Confirm its status | Kobe | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.